SCHEMBL948880

SCHEMBL948880

O=C(O)CN1CCCCC1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
KMT2A Q03164 2/20 0.53
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.49
ACE P12821 3/20 0.46
BLM P54132 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
CYP2C9 P11712 1/20 0.43
CHRM3 P20309 1/20 0.43
CYP2C19 P33261 1/20 0.43
PIK3CD O00329 1/20 0.42
LMNA P02545 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL596327 0.98 TSHR (0.58) TSHRKMT2AHTTL3MBTL1ACE
SCHEMBL11036951 0.98 TSHR (0.58) TSHRKMT2AHTTL3MBTL1ACE
SCHEMBL948990 0.94 TSHR (0.68) TSHRKMT2AHTTACEBLM
SCHEMBL21958786 0.88 TSHR (0.49) TSHRKMT2AHTTL3MBTL1ACE
SCHEMBL6361223 0.85 TSHR (0.50) TSHRKMT2AHTTACEALDH1A1
SCHEMBL43400 0.85
SCHEMBL24263535 0.82 TSHR (0.89) TSHRKMT2AHTTL3MBTL1BLM
SCHEMBL7770891 0.82 TSHR (0.58) TSHRKMT2AHTTL3MBTL1BLM
SCHEMBL6502200 0.82 TSHR (0.58) TSHRKMT2AHTTL3MBTL1BLM
SCHEMBL21389251 0.81 HTT (0.54) TSHRKMT2AHTTL3MBTL1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050165053-A1 Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2005-07-28 US claimed
EP-4536755-B1 COMPOSITIONS COMPRISING SURFACE MODIFIED GLOBULAR NANO-PARTICLES LANDA LABS 2012 LTD (IL) 2026-02-25 EP disclosed
US-20250144039-A1 COMPOSITIONS COMPRISING SURFACE MODIFIED GLOBULAR NANO-PARTICLES LANDA LABS (2012) LTD. (IL) 2025-05-08 US disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 WO disclosed
EP-3645533-B1 TDO2 AND IDO1 INHIBITORS GENENTECH INC (US) 2025-03-26 EP disclosed
WO-2024121046-A1 AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS ANGELINI PHARMA S.P.A. (IT) 2024-06-13 WO disclosed
US-20240132477-A1 Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease PFIZER INC. (US) 2024-04-25 US disclosed
EP-4340951-A1 SKIN CARE COMPOSITIONS COMPRISING NANO-ELEMENTS OF COLLAGEN-SYNTHESIS STIMULATING COMPOUNDS AND METHODS OF PREPARING THE SAME Landa Labs (2012) Ltd. (IL) 2024-03-27 EP disclosed
US-20240082118-A1 TOPICAL COMPOSITIONS AND METHODS OF PREPARING THE SAME LANDA LABS (2012) LTD. (IL) 2024-03-14 US disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 US disclosed
WO-2002022582-A2 SOLID SALT FORMS OF N-[2-[4-[2-(1-METHYLETHOXY)PHENYL]-1-PIPERAZINYL]ETHYL]-2-OXO-1-PIPERIDINEACETAMIDE ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-21 WO disclosed
CN-1264300-A Aryl substituted piperazines useful for treating benign prostatic hypertrophy ORTHO MCNELL PHARMACEUTICAL IN (US) 2000-08-23 CN disclosed
EP-0755374-B1 PROCESS FOR PEPTIDE SEGMENT CONDENSATION MERCK & CO INC (US) 2000-08-16 EP disclosed
US-5773575-A REACTING A CARBOXYLIC ACID AND AMINE WITH COUPLING AGENT MERCK & CO., INC. (US) 1998-06-30 US disclosed
US-5665882-A Pyridyl ethylation of lactams MERCK & CO., INC. (US) 1997-09-09 US disclosed
US-5559232-A ANTICOAGULANTS HOFFMANN-LA ROCHE INC. (US) 1996-09-24 US disclosed
US-5516759-A LHRH antagonists having lactam groups at the N-terminus TAP HOLDINGS INC. (US) 1996-05-14 US disclosed
US-5502165-A AMIDATION OF CARBOXY COMPOOUND WITH AMINE IN WATER AND SOLVENT MERCK & CO., INC. (US) 1996-03-26 US disclosed
CN-1107839-A Carbox amide HOFFMANN LA ROCHE (CH) 1995-09-06 CN disclosed
US-5444075-A Penetration enhancers for transdermal delivery of systemic agents MINASKANIAN GEVORK (US) 1995-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR TSHR 140/4885KMT2A 3040/4885HTT 722/4885
US-20240132477-A1 Benzimidazole Derivatives and Their Use As Inhibitors of ITK For The Treatment of Skin Disease ITK, BLK, BCKDK TSHR 3281/4885KMT2A 2121/4885HTT 3979/4885
US-20050165053-A1 Substituted4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, CASP2 TSHR 2858/4885KMT2A 3051/4885HTT 2330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.